Medical management of brain metastases

Neurosurgery Clinics of North America

Volumn 22, Issue 1, 2011, Pages 27-36

  Butowski, Nicholas ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adult; Brain metastases; Chemotherapy; Medical oncology

Indexed keywords

ANTICONVULSIVE AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYTOTOXIC AGENT; DEXAMETHASONE; ETOPOSIDE; FLUOROURACIL; FOTEMUSTINE; GEMCITABINE; LAPATINIB; NAVELBINE; NITROSOUREA; PLATINUM COMPLEX; TEMOZOLOMIDE; TENIPOSIDE; TOPOTECAN;

BONE MARROW SUPPRESSION; BRAIN EDEMA; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CLINICAL TRIAL; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG TOLERABILITY; FATIGUE; HUMAN; IMMUNE DEFICIENCY; MULTIPLE CYCLE TREATMENT; NEUROSURGERY; NONHUMAN; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIATION DOSE; REVIEW; SEIZURE; STEREOTACTIC RADIOSURGERY; WHOLE BRAIN RADIATION THERAPY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTINEOPLASTIC PROTOCOLS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DRUG THERAPY; HUMANS; RADIOTHERAPY;

EID: 78649424825     PISSN: 10423680     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nec.2010.08.004     Document Type: Review

References (63)

1. Walbert T., Gilbert M.R. The role of chemotherapy in the treatment of patients with brain metastases from solid tumors. Int J Clin Oncol 2009, 14(4):299-306.
2. Gavrilovic I.T., Posner J.B. Brain metastases: epidemiology and pathophysiology. J Neurooncol 2005, 75(1):5-14.
3. Chamberlain MC. Brain metastases: a medical neuro-oncology perspective. Expert Rev Neurother 2010;10(4):563-73.
4. Norden A.D., Wen P.Y., Kesari S. Brain metastases. Curr Opin Neurol 2005, 18(6):654-661.
5. Ammirati M., et al. The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010, 96(1):85-96.
6. Robinson P.D., et al. Methodology used to develop the AANS/CNS management of brain metastases evidence-based clinical practice parameter guidelines. J Neurooncol 2010, 96(1):11-16.
7. Sperduto P.W., et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4259 patients. Int J Radiat Oncol Biol Phys 2010, 77(3):655-661.
8. Soffietti R., Ruda R., Trevisan E. Brain metastases: current management and new developments. Curr Opin Oncol 2008, 20(6):676-684.
9. Yamanaka R. Medical management of brain metastases from lung cancer. Oncol Rep 2009, 22(6):1269-1276.
10. Soffietti R., Ruda R., Mutani R. Management of brain metastases. J Neurol 2002, 249(10):1357-1369.
11. Lee S.S., et al. Brain metastases in breast cancer: prognostic factors and management. Breast Cancer Res Treat 2008, 111(3):523-530.
12. Lagerwaard F.J., et al. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 1999, 43(4):795-803.
13. Meier S., et al. Survival and prognostic factors in patients with brain metastases from malignant melanoma. Onkologie 2004, 27(2):145-149.
14. Golden D.W., et al. Prognostic factors and grading systems for overall survival in patients treated with radiosurgery for brain metastases: variation by primary site. J Neurosurg 2008, 109:77-86.
15. Chidel M.A., et al. Application of recursive partitioning analysis and evaluation of the use of whole brain radiation among patients treated with stereotactic radiosurgery for newly diagnosed brain metastases. Int J Radiat Oncol Biol Phys 2000, 47(4):993-999.
16. Gaspar L., et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997, 37(4):745-751.
17. Thomas S.S., Dunbar E.M. Modern multidisciplinary management of brain metastases. Curr Oncol Rep 2010, 12(1):34-40.
18. Sperduto P.W., et al. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 2008, 70(2):510-514.
19. Ewend M.G., et al. Guidelines for the initial management of metastatic brain tumors: role of surgery, radiosurgery, and radiation therapy. J Natl Compr Canc Netw 2008, 6(5):505-513. [quiz: 514].
20. Mornex F., et al. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res 2003, 13(1):97-103.
21. Soffietti R., et al. EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force. Eur J Neurol 2006, 13(7):674-681.
22. Linskey M.E., Kalkanis S.N. Evidence-linked, clinical practice guidelines-getting serious; getting professional. J Neurooncol 2010, 96(1):1-5.
23. Gaspar L.E., et al. The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010, 96(1):17-32.
24. Mintz A., et al. Management of single brain metastasis: a practice guideline. Curr Oncol 2007, 14(4):131-143.
25. Tsao M.N., et al. Whole-brain radiotherapy for the treatment of multiple brain metastases. Cochrane Database Syst Rev 2006, 3. CD003869.
26. Nieder C., Berberich W., Schnabel K. Tumor-related prognostic factors for remission of brain metastases after radiotherapy. Int J Radiat Oncol Biol Phys 1997, 39(1):25-30.
27. Kalkanis S.N., et al. The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010, 96(1):33-43.
28. Linskey M.E., et al. The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010, 96(1):45-68.
29. Andrews D.W., et al. Whole-brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004, 363(9422):1665-1672.
30. Sawrie S.M., et al. Predictors of distant brain recurrence for patients with newly diagnosed brain metastases treated with stereotactic radiosurgery alone. Int J Radiat Oncol Biol Phys 2008, 70(1):181-186.
31. Gerstner E.R., Fine R.L. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol 2007, 25(16):2306-2312.
32. Seute T., et al. Response of asymptomatic brain metastases from small-cell lung cancer to systemic first-line chemotherapy. J Clin Oncol 2006, 24(13):2079-2083.
33. Antonadou D., et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 2002, 20(17):3644-3650.
34. Verger E., et al. Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys 2005, 61(1):185-191.
35. Addeo R., et al. Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases. Cancer 2008, 113(9):2524-2531.
36. Guerrieri M., et al. A randomised phase III study of palliative radiation with concomitant carboplatin for brain metastases from non-small cell carcinoma of the lung. Lung Cancer 2004, 46(1):107-111.
37. Kim D.Y., et al. Efficacy of platinum-based chemotherapy after cranial radiation in patients with brain metastasis from nonsmall cell lung cancer. Oncol Rep 2005, 14(1):207-211.
38. Postmus P.E., et al. Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy-a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 2000, 18(19):3400-3408.
39. Robinet G., et al. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of nonsmall cell lung cancer: Groupe Francais de Pneumo-Cancerologie (GFPC) Protocol 95-1. Ann Oncol 2001, 12(1):59-67.
40. Lee D.H., et al. Primary chemotherapy for newly diagnosed nonsmall cell lung cancer patients with synchronous brain metastases compared with whole-brain radiotherapy administered first: result of a randomized pilot study. Cancer 2008, 113(1):143-149.
41. McWilliams R.R., et al. Melanoma-induced brain metastases. Expert Rev Anticancer Ther 2008, 8(5):743-755.
42. Schild S.E., et al. Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy?. Am J Clin Oncol 2009.
43. Mehta M.P., et al. The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010, 96(1):71-83.
44. Olson J.J., et al. The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics. J Neurooncol 2010, 96(1):115-142.
45. Peacock K.H., Lesser GJ Current therapeutic approaches in patients with brain metastases. Curr Treat Options Oncol 2006, 7(6):479-489.
46. Shimato S., et al. EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib. Neuro Oncol 2006, 8(2):137-144.
47. Namba Y., et al. Gefitinib in patients with brain metastases from nonsmall cell lung cancer: review of 15 clinical cases. Clin Lung Cancer 2004, 6(2):123-128.
48. Hotta K., et al. Effect of gefitinib (Iressa, ZD1839) on brain metastases in patients with advanced nonsmall cell lung cancer. Lung Cancer 2004, 46(2):255-261.
49. Ceresoli G.L., et al. Gefitinib in patients with brain metastases from nonsmall cell lung cancer: a prospective trial. Ann Oncol 2004, 15(7):1042-1047.
50. Chiu C.H., et al. Gefitinib is active in patients with brain metastases from nonsmall cell lung cancer and response is related to skin toxicity. Lung Cancer 2005, 47(1):129-138.
51. Yano S., et al. Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res 2000, 60(17):4959-4967.
52. Besse B., et al. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 2010, 16(1):269-278.
53. Socinski M.A., et al. Safety of bevacizumab in patients with nonsmall cell lung cancer and brain metastases. J Clin Oncol 2009, 27(31):5255-5261.
54. Arslan C., Dizdar O., Altundag K. Systemic treatment in breast-cancer patients with brain metastasis. Expert Opin Pharmacother 2010, 11(7):1089-1100.
55. Ryken T.C., et al. The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010, 96(1):103-114.
56. Ricciardi S., de Marinis F. Multimodality management of nonsmall cell lung cancer patients with brain metastases. Curr Opin Oncol 2010, 22(2):86-93.
57. Kaal E.C., Taphoorn M.J., Vecht C.J. Symptomatic management and imaging of brain metastases. J Neurooncol 2005, 75(1):15-20.
58. Koehler P.J. Use of corticosteroids in neuro-oncology. Anticancer Drugs 1995, 6(1):19-33.
59. Mikkelsen T., et al. The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010, 96(1):97-102.
60. Gaspar L.E., et al. Preisrradiation evaluation and management of brain metastases. American College of Radiology. ACR appropriateness criteria. Radiology 2000, 215:1105-1110.
61. Hempen C., Weiss E., Hess C.F. Dexamethasone treatment in patients with brain metastases and primary brain tumors: do the benefits outweigh the side effects?. Support Care Cancer 2002, 10(4):322-328.
62. Forsyth P.A., et al. Prophylactic anticonvulsants in patients with brain tumour. Can J Neurol Sci 2003, 30(2):106-112.
63. Glantz M.J., et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000, 54(10):1886-1893.